menu

CME: To Switch or Not to Switch: Identification & Addressing Treatment Failure in Ophthalmology

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

To Switch or Not to Switch: Identification & Addressing Treatment Failure in Ophthalmology

Program Information
Recommended
To Switch or Not to Switch: Identification & Addressing Treatment Failure in Ophthalmology
RestartResume
Discover the latest insights on age-related macular degeneration, diabetic macular edema, and retinal vein occlusion.

Available credits: 1.00

Time to complete: 60 minutes

Released:

Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Dr. Rishi Singh leads a panel of expert ophthalmologists, including Drs. Sophia Bakri, Jay Duker, and Judy Kim, to discuss age-related macular degeneration (AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO). Topics in this conversation include medication selection for these diseases, pivotal trial data, switching therapies, and a patient case discussion. 

  • Provider

    Jointly provided by AKH Inc., Advancing Knowledge in Healthcare and iVista Medical Education, Inc. 

  • Target Audience

    This activity is designed to meet the needs of retina specialists, retina fellows, comprehensive ophthalmologists and healthcare providers who are interested in learning about retinal diseases.

  • Learning Objectives

    Upon completion of the educational activity, participants should be able to:

    • Identify medications for age-related macular degeneration (AMD), diabetic macular edema (DME), and Retinal vein occlusion (RVO) based on specific patient characteristics and preferences
    • Initiate and step through therapies optimally within a restricted reimbursement environment
    • Describe how clinical trial results differentiate treatments based on functional, anatomic, and visual outcomes
    • Choose therapies in AMD, DME, and RVO based on measured outcomes
  • Accreditation and Credit Designation Statements

    Criteria for Success
    In order to receive credit, participants must complete the pre-assessment questions, post-test, and program evaluation. Participants must also score at least 70% on the post-test. Certificates will be distributed online at the conclusion of the activity. If you have questions about this CME activity, please contact AKH Inc. at jgoldman@akhcme.com.

     CME Credit provided by AKH Inc., Advancing Knowledge in Healthcare

    Physicians
    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and iVista Medical Education, Inc. AKH Inc., Advancing Knowledge in Healthcare is accredited by the ACCME to provide continuing medical education for physicians.


    AKH Inc., Advancing Knowledge in Healthcare designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Physician Assistants
    NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME.

  • Disclosure of Conflicts of Interest

    FACULTY DISCLOSURES

    NAME

    RELATIONSHIP

    COMPANY

    Sophie J. Bakri, MD

    Consultant

    Allegro Ophthalmics, LLC.; Allergan plc; Alimera Sciences, Inc.; EyePoint Pharmaceuticals; Novartis International AG

    Jay S. Duker, MD

    Board of Directors

    EyePoint Pharmaceuticals; Sesen Bio

     

    Consultant

    Allegro Ophthalmics, LLC.; Allergan plc; Aura Biosciences, Inc.; Beyeonics Surgical Ltd.; Helio Vision, Inc.; Novartis International AG; F. Hoffmann-La Roche Ltd; Santen Pharmaceutical Co., Ltd.; Sigilon Therapeutics, Inc.

     

    Contracted Research

    Carl Zeiss Meditec AG

     

    Stock

    Hemera Biosciences

    Judy E. Kim, MD

    Consultant

    EyePoint Pharmaceuticals; Genentech, Inc.; Kodiak Sciences Inc.; Notal Vision, Inc.; Novartis International AG

     

    Research Equipment

    Notal Vision, Inc.; Optos plc

    Rishi P. Singh, MD

    Consultant

    Alcon, a Novartis division; Carl ZEISS Meditec, Inc.; Genentech, Inc.; Novartis International AG; Optos plc; Regeneron Pharmaceuticals, Inc.

    PLANNER DISCLOSURES

    Dorothy Caputo, MA, BSN, RN - CE Director of Accreditations

    N/A

    Nothing to disclose

    iVista Staff and Planners

    N/A

    Nothing to disclose

    AKH Planners and Reviewers

    N/A

    Nothing to disclose

  • Commercial Support

    This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.

  • Disclosures

    It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by AKH prior to accreditation of the activity and may include any of or combination of the following: attestation to non-commercial content; notification of independent and certified CME/CE expectations; referral to National Author Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other author for discussion of recommendations; independent review against criteria ensuring evidence support recommendation; moderator review; and peer review. 

    Disclosure of Unlabeled Use and Investigational Product
    This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

  • Disclaimer

    This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio

Loading...

Programs 9/22/19

Get a Dose of ReachMD in Your Inbox
and Practice Smarter Medicine

Stay current with the best in medical education.